The Gazette offers audio versions of articles using Instaread. Some words may be mispronounced. WASHINGTON (AP) — In a potential leap forward in the global fight against the pandemic, drugmaker Merck ...

An at-home pill against coronavirus halves the chance that people newly diagnosed with COVID-19 will land in the hospital or die, early results released by the drug’s developer ...

Pharmaceutical company Merck announced Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus. The company said it ...

The FDA said Friday that Merck's anti-COVID-19 pill is effective in treating the virus but said that regulators will meet next week to investigate whether the pill is safe for people who are pregnant ...

UK approval for molnupiravir comes ahead of U.S. decision UK and NHS to confirm deployment plans in due course UK secured just under half a million courses last month Drug will be given to higher risk ...

Drugmaker Merck has officially asked the FDA to authorize its pill for COVID-19, saying it can reduce the risk of hospitalization. But, just how much of a gamechanger could it really be? READ MORE: ...

The Bill and Melinda Gates Foundation says it will spend $120 million to boost access to generic versions of drugmaker Merck’s antiviral COVID-19 pill for lower income countries, if the drug gets ...

WASHINGTON - U.S. health regulators on Thursday authorized Merck’s COVID-19 pill, known as molnupiravir — the second medication approved for at-home use to battle the rapidly-spreading omicron variant ...

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

WASHINGTON - Pfizer said Tuesday that its experimental COVID-19 pill appears effective against the omicron variant. The company also said full results of its 2,250-person study confirmed the pill's ...